3 completed, 3 unknown, 2 recruiting, 1 active not recruiting. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 3, Unknown 3, Recruiting 2, Active not recruiting 1 |
| Phase 2 | 5 | Unknown 3, Active not recruiting 1, Recruiting 1 |
Follow GIST: new trials by email Literature Review of GIST trials Research Report on GIST
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lenvatinib After Progression on Imatinib, Sunitinib, and Regorafenib for GIST Patients Lenvatinib Capsules - GIST | Phase 1 / Phase 2 | Recruiting | Asan Medical Center | 48 | 2025-10-29 | 2026-04-03 |
| Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors Lutetium Lu 177-Edotreotide, Amino Acid Solution - Somatostatin Receptor Positive, NETs | Phase 1 | Recruiting | ITM Solucin GmbH | 20 | 2025-09-26 | 2026-10-27 |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies Inlexisertib, Ripretinib - GIST | Phase 1 / Phase 2 | Active not recruiting | Deciphera Pharmaceuticals, LLC | 94 | 2023-09-28 | 2026-10-20 |
| A Drug-drug Interaction Study of Avapritinib and Midazolam Avapritinib, midazolam - Gastrointestinal Stromal Tumors, GIST | Phase 1 | Completed | Blueprint Medicines Corporation | 10 | 2022-08-24 | 2024-12-13 |
| Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy Stereotactic radiotherapy - Neuroendocrine Carcinoma of Pancreas, Duodenum Carcinoma | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 33 | 2020-12-01 | 2022-12-07 |
| Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST) Selinexor, Imatinib - Maximum Tolerated Dose, GIST | Phase 1 / Phase 2 | Unknown | Grupo Espanol de Investigacion en Sarcomas | 30 | 2019-08-16 | 2023-03-27 |
| A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib - Colorectal Cancer Not MSI-H or MMR-deficient, GIST | Phase 1 / Phase 2 | Unknown | Institut Bergonié | 747 | 2018-05-04 | 2023-03-03 |
| Vaccine Therapy in Treating Patients With Metastatic Solid Tumors HER-2 vaccine, Extension HER-2 vaccine trial at OBD - Malignant Solid Tumour, Breast Cancer | Phase 1 | Completed | Robert Wesolowski | 65 | 2011-06-21 | 2023-09-15 |
| Perifosine + Sunitinib Malate for Patients With Advanced Cancers Perifosine, Sunitinib Malate - Renal Cancer, GIST | Phase 1 | Completed | AEterna Zentaris | 15 | 2006-10-01 | 2014-02-19 |
Gastro-enteropancreatic neuroendocrine tumor (2) · Gastrointestinal Stromal Tumors (2) · Neoplasm Metastasis (2) · Sarcoma (2) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Central Nervous System Neoplasms (1) · Colonic Neoplasms (1) · Drug-Related Side Effects and Adverse Reactions (1) · Duodenal Neoplasms (1) · Glioblastoma (1)
Neoplasms (7) · Digestive System Diseases (5) · Digestive System Neoplasms (5) · Gastrointestinal Diseases (5) · Gastrointestinal Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Connective and Soft Tissue (5) · Pathological Conditions, Signs and Symptoms (4) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Neoplasms, Glandular and Epithelial (3) · Pathologic Processes (3)
177Lu-octreotide, DOTA(0)-Tyr(3)- (1) · CHP-HER2 vaccine (1) · Clinical Trials, Phase II as Topic (1) · Drug Combinations (1) · Imatinib Mesylate (1) · Midazolam (1) · Pharmaceutical Preparations (1) · Radiosurgery (1) · Sunitinib (1) · amino-acid, glucose, and electrolyte solution (1) · avapritinib (1) · lenvatinib (1) · perifosine (1) · regorafenib (1) · ripretinib (1)
AEterna Zentaris (1) · Asan Medical Center (1) · Blueprint Medicines Corporation (1) · Deciphera Pharmaceuticals, LLC (1) · Erasmus Medical Center (1) · Grupo Espanol de Investigacion en Sarcomas (1) · ITM Solucin GmbH (1) · Institut Bergonié (1) · Robert Wesolowski (1)
United States (4) · France (3) · Spain (3) · Netherlands (2) · Denmark (1) · Germany (1) · Italy (1) · Portugal (1) · South Korea (1) · Switzerland (1)
Cesar Serrano, MD (1) · Robert Wesolowski, MD (1) · Roman Henkel, PhD (1)
PMID 34965951, PMID 34998048, PMID 39317507, PMID 40204996, PMID 40579407
2016 (1), 2017 (1)